EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and Safety of Topical 1.5% Ruxolitinib for Chronic Hand Eczema in Real‑World Practice

Meerab Majeed iD, Christopher Shenouda iD, Ahmad Al-Hajji, Ghada AlHayaza iD, Mohannad Abu-Hilal iD

Journal of Cutaneous Medicine and Surgery · 22.06.2026

DOI: 10.1177/12034754261460065 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cutaneous Medicine and Surgery, online erschienen am 22.06.2026. Verfasst von Meerab Majeed und 4 weiteren Autor:innen. Beteiligte Einrichtung: Temerty Faculty of Medicine, University of Toronto, ON, Canada. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic hand eczema (CHE) is defined as hand eczema persisting for >3 months or recurring at least twice within 12 months and is associated with significant pruritus, pain, functional impairment, and psychosocial burden. Conventional treatments are frequently inadequate or limited by adverse events (AEs). Topical Janus kinase inhibitors represent a novel therapeutic option. While delgocitinib has recently been approved for CHE, emerging evidence suggests topical ruxolitinib may also be effective.

Objectives

To evaluate the real-world efficacy and safety of topical ruxolitinib 1.5% cream in patients with moderate-to-severe CHE.

Methods

This retrospective real-world case series included 13 patients with CHE treated with ruxolitinib 1.5% cream applied twice daily for ~12 weeks. Baseline demographic and clinical characteristics were collected, including CHE subtype and disease severity. Treatment response was assessed using the Physician’s Global Assessment (PGA).

Results

The cohort included 8 females and 5 males with a mean age of 33.8 years and mean disease duration of 6.9 years. Most patients had hyperkeratotic CHE (76.9%), with all exhibiting moderate-to-severe disease at baseline (PGA 3-4). By week 12, 92.3% of patients achieved a PGA score of 0 or 1, indicating clear or almost clear disease. No treatment-related AEs were reported during follow-up.

Conclusions

Topical ruxolitinib demonstrated high rates of clinical improvement and favorable tolerability in this real-world CHE cohort. Despite limitations including small sample size and retrospective design, these findings support ruxolitinib as a promising option for recalcitrant CHE and warrant confirmation in larger randomized controlled trials.

Schlagwörter

Stichwörter der Autor:innen

chronic hand dermatitischronic hand eczemaquality of liferuxolitinibtopical JAK inhibitors

Autor:innen und Institutionen

  • Temerty Faculty of Medicine, University of Toronto, ON, Canada.
  • Michael G. DeGroote School of Medicine, McMaster University, Hamilton ON, Canada.
  • Division of Dermatology, McMaster University, Hamilton, ON, Canada.

ORCID-Profile: Meerab Majeed, Christopher Shenouda, Ghada AlHayaza, Mohannad Abu-Hilal

Zitieren

APA

Majeed, M., Shenouda, C., Al-Hajji, A., AlHayaza, G., & Abu-Hilal, M. (2026). Efficacy and Safety of Topical 1.5% Ruxolitinib for Chronic Hand Eczema in Real‑World Practice. Journal of Cutaneous Medicine and Surgery. https://doi.org/10.1177/12034754261460065

Vancouver

Majeed M, Shenouda C, Al-Hajji A, AlHayaza G, Abu-Hilal M. Efficacy and Safety of Topical 1.5% Ruxolitinib for Chronic Hand Eczema in Real‑World Practice. Journal of Cutaneous Medicine and Surgery. 2026. doi:10.1177/12034754261460065

BibTeX
@article{Majeed2026,
  author = {Majeed, Meerab and Shenouda, Christopher and Al-Hajji, Ahmad and AlHayaza, Ghada and Abu-Hilal, Mohannad},
  title = {Efficacy and Safety of Topical 1.5% Ruxolitinib for Chronic Hand Eczema in Real‑World Practice},
  journal = {Journal of Cutaneous Medicine and Surgery},
  year = {2026},
  doi = {10.1177/12034754261460065}
}
Kostenlos starten →